Search Results - "Ramanathan, R. K."

Systematic review of first-in-human and early phase clinical trials for surgically implantable biological mitral valve substitutes by Sazzad, Faizus, Tan, Ying Kiat, Chan, Li Xuan Beverly, Moideen, Irwan Shah Bin Mohd, Gohary, Abdulrahman El, Stevens, John C, Ramanathan, K. R, Kofidis, Theo

“…Abstract Background The aim of this review was the creation of uniform protocols to carry out and disclose First-In-Human and preliminary clinical trials of…”
Get full text

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer by Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., Kindler, H. L.

“…Background: This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients…”
Get full text

Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT by Hochster, H.S., Grothey, A., Hart, L., Rowland, K., Ansari, R., Alberts, S., Chowhan, N., Ramanathan, R.K., Keaton, M., Hainsworth, J.D., Childs, B.H.

“…Oxaliplatin is an integral component of colorectal cancer treatment, but its use is limited by neurotoxicity. The Combined Oxaliplatin Neurotoxicity Prevention…”
Get full text

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies by Mahadevan, D, Chiorean, E.G, Harris, W.B, Von Hoff, D.D, Stejskal-Barnett, A, Qi, W, Anthony, S.P, Younger, A.E, Rensvold, D.M, Cordova, F, Shelton, C.F, Becker, M.D, Garlich, J.R, Durden, D.L, Ramanathan, R.K

“…Abstract Background SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum…”
Get full text

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma by Patnaik, A, Weiss, G J, Papadopoulos, K P, Hofmeister, C C, Tibes, R, Tolcher, A, Isaacs, R, Jac, J, Han, M, Payumo, F C, Cotreau, M M, Ramanathan, R K

“…Background: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1κ inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D),…”
Get full text

Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741 by Delaunoit, T., Alberts, S. R., Sargent, D. J., Green, E., Goldberg, R. M., Krook, J., Fuchs, C., Ramanathan, R. K., Williamson, S. K., Morton, R. F., Findlay, B. P.

“…Background: Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS)…”
Get full text

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282 by Ramanathan, R. K., Cnaan, A., Hahn, R. G., Carbone, P. P., Haller, D. G.

“…Background: A phase II study of dacarbazine (DTIC), was conducted to determine the response rate, duration of response, toxicity and overall survival of…”
Get full text

Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies by Zamboni, WC, Strychor, S, Maruca, L, Ramalingam, S, Zamboni, BA, Wu, H, Friedland, DM, Edwards, RP, Stoller, RG, Belani, CP, Ramanathan, RK

“…S‐CKD602 is a pegylated liposomal formulation of CKD‐602. This study is the first to evaluate the factors affecting the high interpatient variability in the…”
Get full text

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas by Patnaik, A., Appleman, L.J., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Weiss, G.J., Sachdev, J.C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J.M., Lotze, M.T., Toledo, F.G.S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R.K.

“…To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients…”
Get full text

Anaesthesia for Angelman syndrome by Ramanathan, K. R., Muthuswamy, D., Jenkins, B. J.

“…Summary We describe the administration of anaesthesia to a patient with Angelman syndrome, which is characterised by an abnormality of chromosome 15, where a…”
Get full text

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer by Chiorean, E.G., Von Hoff, D.D., Reni, M., Arena, F.P., Infante, J.R., Bathini, V.G., Wood, T.E., Mainwaring, P.N., Muldoon, R.T., Clingan, P.R., Kunzmann, V., Ramanathan, R.K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.

“…A phase I/II study and subsequent phase III study (MPACT) reported significant correlations between CA19-9 decreases and prolonged overall survival (OS) with…”
Get full text

Effects of vagus nerve stimulation on extinction of conditioned fear and post-traumatic stress disorder symptoms in rats by Noble, L J, Gonzalez, I J, Meruva, V B, Callahan, K A, Belfort, B D, Ramanathan, K R, Meyers, E, Kilgard, M P, Rennaker, R L, McIntyre, C K

“…Exposure-based therapies help patients with post-traumatic stress disorder (PTSD) to extinguish conditioned fear of trauma reminders. However, controlled…”
Get full text

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas by Ramanathan, R.K., Goldstein, D., Korn, R.L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D.D.

“…In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic…”
Get full text

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline by Ramanathan, R.K., Korn, R.L., Chiorean, E.G., Liu, H., Von Hoff, D.D.

“…A recent analysis from the MPACT trial supported the use of carbohydrate antigen 19-9 (CA19-9) decrease as a predictive marker for survival in patients…”
Get full text

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer by BELANI, C. P, KEARNS, C. M, EGORIN, M. J, ZUHOWSKI, E. G, ERKMEN, K, HIPONIA, D, ZACHARSKI, D, ENGSTROM, C, RAMANATHAN, R. K, CAPOZZOLI, M. J, AISNER, J

“…To determine the maximum-tolerated dose of paclitaxel with carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung…”
Get full text

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer by El-Khoueiry, A. B., Ramanathan, R. K., Yang, D. Y., Zhang, W., Shibata, S., Wright, J. J., Gandara, D., Lenz, H. J.

“…Summary Purpose Patients with metastatic pancreatic cancer have limited therapeutic options. The role of the Ras-Raf-MAPK pathway and of vascular endothelial…”
Get full text

Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies by Ramanathan, R.K., Rothenberg, M.L., de Gramont, A., Tournigand, C., Goldberg, R.M., Gupta, S., André, T.

“…The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence, severity, and/or course of peripheral…”
Get full text

Chemotherapy for advanced non-small cell lung cancer: past, present, and future by Ramanathan, R K, Belani, C P

“…Until recently, chemotherapeutic intervention in advanced and metastatic non-small cell lung cancer (NSCLC) has been viewed with a certain degree of nihilism…”
Get more information

Pulmonary infiltrates following administration of paclitaxel by Ramanathan, R K, Reddy, V V, Holbert, J M, Belani, C P

“…The clinical spectrum of hypersensitivity reactions reported with paclitaxel has not included the occurrence of pulmonary infiltrates. This report describes…”
Get more information

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer by RAMANATHAN, Ramesh K, LEE, Kenneth M, DAY, Roger, TROETSCHEL, Monica, FINN, Olivera J, MCKOLANIS, John, HILTBOLD, Elizabeth, SCHRAUT, Wolfgang, MOSER, Arthur J, WARNICK, Elizabeth, WHITESIDE, Theresa, OSBORNE, Jennifer, HYOUNG KIM

“…MUC1 is a glycoprotein overexpressed in tumors as a hypoglycosylated form. A vaccine composed of a 100-amino acid peptide corresponding to five 20-amino acid…”
Get full text